AJP - Renal Fuel your research with LabChart
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Am J Physiol Renal Physiol 271: F1061-F1067, 1996;
0363-6127/96 $5.00
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kelly, K. J.
Right arrow Articles by Bonventre, J. V.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kelly, K. J.
Right arrow Articles by Bonventre, J. V.

AJP - Renal Physiology, Vol 271, Issue 5 1061-F1067, Copyright © 1996 by American Physiological Society

ARTICLES

An oral platelet-activating factor antagonist, Ro-24-4736, protects the rat kidney from ischemic injury

K. J. Kelly, N. E. Tolkoff-Rubin, R. H. Rubin, W. W. Williams Jr, S. M. Meehan, C. L. Meschter, J. G. Christenson and J. V. Bonventre
Medical Service, Massachusetts General Hospital, Boston, USA.

The role of platelet-activating factor (PAF) in ischemic acute renal failure was evaluated by administering an oral PAF antagonist (Ro-24-4736) to rats prior to or after interruption of blood flow to both kidneys for 30 min. In animals treated with the PAF antagonist prior to ischemia, renal function was less impaired and histological abnormalities was less pronounced when compared with postischemic kidneys from vehicle-treated animals. Serum creatinine (mg/ dl) 24 h following renal ischemia was 1.58 +/- 0.17 in the PAF antagonist-treated rats compared with 2.19 +/- 0.15 in rats given placebo (P < 0.01). There was less necrosis in the outer medulla of kidneys of PAF antagonist-treated animals (P < 0.01). Tissue myeloperoxidase activity at 48 and 72 h postischemia was lower in kidneys of PAF antagonist-treated rats (P < 0.05). The PAF antagonist was also protective when administered 30 min but not 2 h following the ischemic insult. The coincident use of anti-intercellular adhesion molecule-1 monoclonal antibody did not confer additional protection over that observed with the oral PAF antagonist alone. These data suggest that PAF contributes to the pathophysiology of renal ischemic injury, perhaps by its effects on leukocyte-endothelial interactions. An orally active PAF antagonist can protect against the development of ischemic acute renal failure.


This article has been cited by other articles:


Home page
 J. Am. Soc. Nephrol.Home page
J. V. Bonventre and J. M. Weinberg
Recent Advances in the Pathophysiology of Ischemic Acute Renal Failure
J. Am. Soc. Nephrol., August 1, 2003; 14(8): 2199 - 2210.
[Full Text] [PDF]

Home page
 J. Am. Soc. Nephrol.Home page
N. LAMEIRE and R. VANHOLDER
Pathophysiologic Features and Prevention of Human and Experimental Acute Tubular Necrosis
J. Am. Soc. Nephrol., February 1, 2001; 12(90001): 20S - 32.
[Abstract] [Full Text]

Home page
 Am. J. Physiol. Renal Physiol.Home page
W. Lieberthal and S. K. Nigam
Acute renal failure. II. Experimental models of acute renal failure: imperfect but indispensable
Am J Physiol Renal Physiol, January 1, 2000; 278(1): F1 - F12.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Visit Other APS Journals Online